Pulmonary gas exchange after foam sclerotherapy by L. Moro et al.
Copyright 2013 American Medical Association. All rights reserved.
Letters
RESEARCH LETTER
Pulmonary Gas ExchangeAfter FoamSclerotherapy
Foam sclerotherapy (FS) is a safe and effective procedure.
Indeed, transient ischemic attacks and pulmonary compli-
cations are usually mild, although stroke and pulmonary
embolism events have occasionally been reported.1 It has
been speculated that gas microemboli, passing through the
heart, may reach the lungs or, through a right-to-left shunt,
the cerebral arteries. However, no treatment modification
could completely prevent the cephalic dissemination of air
bubbles. In an analogy with decompression sickness, a
venous gas microembolization should lead to some loss
of gas exchange surface, with consequent gas exchange
abnormalities and reduction in the transfer factor of the
lung for carbon monoxide (TLCO). The aim of this proof-of-
concept study was to verify whether TLCO worsens after FS
treatment.
Methods | Eleven consecutive voluntary patients, scheduled
to undergo FS for varicose veins, were enrolled in the study.
The study was approved by the local ethics committee.
Written informed consent was obtained from participants.
Exclusion criteria were history of thromboembolism, mobil-
ity impairment, contraindications to compression, and pul-
monary and/or heart disease. Respiratory function tests
(RFTs) were performed after an overnight fast and 24 hours
of being smoke free using a Baires Computerized System
(Biomedin) as described elsewhere.2 The following
parameters were obtained and adjusted for hemoglobin
concentration: TLCO, CO diffusion index (through the
alveolus-capillary barrier), and KCO (ie, TLCO adjusted for
alveolar volume). Foam sclerotherapy was performed
mixing polidocanol, 1%, with physiological gas (70% CO2,
30% O2) to constitute the final volume of foam to inject.
Nine and 2 patients had the great saphenous vein (GSV)
and the small saphenous vein (SSV) treated, respectively.
Procedures conformed to the European Consensus on
Foam Sclerotherapy guidelines. The mean (SD) volume of
injected foam was 6.00 (2.82) cm3 in SSV and 6.25 (1.67) cm3
in GSV.
The timetable of the study was as follows:
• General clinical assessment
• After 10 minutes, RFT (time 0, T0)
• After 10 minutes, sclerotherapy
• After 20 minutes, RFT (time 1, T1)
• After 7 days, RFT (time 2, T2)
Results from RFT at T0, T1, and T2 were compared using
t test analyses.
Results | Patients (7women and 4men) had amean (SD) age of
64 (12) years.Noneof thepatients reported adverse events re-
sulting fromtheFS.Nostatistically significantdifferenceacross
study time points was reported for RFTs (P > .05 for all com-
parisons) (Table). To limit the risk of having obtained false-
negative results, detectable alternative analyses were per-
formed (α = .05; P = .80).
Our studywas powered to detect true differences of 0.57,
2.42, 4.16, 0.22, 1.54, 5.99, 8.05, and0.46at theTLCO (T1 − T0),
TLCO% (T1 − T0), KCO (alveolar volume [AV]) (T1 − T0), KCO%
(T1 − T0),TLCO (T2 − T0),TLCO%(T2 − T0),KCO (AV) (T2 − T0),
and KCO% (T2 − T0), respectively. Because these values can-
not be considered as clinically relevant, we may assume our
results as likely to be truly negative.
Discussion |Lungbubblemicroembolismseemsunlikely tocom-
plicateFS,at least if aCO2/O2-basedmixture,which is less likely
to cause an embolism than an air-based one, is used.3,4 Al-
though theonset of pulmonary embolism followingFS is neg-
ligible, dry cough and chest tightness are frequently re-
ported. Their pathogenesismight be related to endothelin-1,5
involved in the mechanism of cough through modulation
of the transient receptor potential vanilloid 1 (TRPV1), ex-
pressed by airway sensory nerves and involved in the genesis
of cough.6 It is possible that gas exchangemodificationsmay
occur in thecaseofmajor respiratoryalterations.However, the
TLCO parameter we adopted is highly sensitive even to clini-
cally silent modifications. Neurological adverse effects of FS
have been reported within a few minutes from the foam in-
jection. Therefore, wemight have underestimated some pul-
monaryeffectowing to the timeneeded for thepatient todress
and be transferred to the RFT examination.
Table. Pulmonary Function Indexes Gas Exchange at Baseline (T0), 20Minutes (T1) and 1Week (T2) After Foam Sclerotherapy andMean (SD)
Difference Between T1 – T0 and T2 – T0a
T0 T1 T2 Δ T1 − T0 P Value Δ T2 − T0 P Value
TLCO (AV), mL/min/mm Hg 17.95 (4.77) 18.23 (4.59) 17.99 (4.83) 0.27 (0.61) .17 −0.39 (1.64) .94
TLCO (AV), % 73.90 (14.69) 75.36 (13.85) 74.45 (16.68) 1.46 (2.58) .09 −0.55 (6.39) .78
KCO, measured 4.04 (1.41) 4.01 (1.34) 4.07 (1.76) 0.64 (4.43) .64 0.00 (8.59) >.99
KCO, % 70.27 (21.26) 69.64 (19.97) 70.27 (26.14) 0.32 (0.24) .67 −0.03 (0.49) .84
Abbreviations: AV, alveolar volume; KCO, TLCO adjusted for alveolar volume;
TLCO, factor of the lung for carbonmonoxide.
a Data are given as means (SDs).
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Nevertheless, no sign or symptom was reported by our
patients in this timeframe.
Conclusions | Bubble microembolism either is not a typical ef-
fectofFSorhasonlyaminimal impactongasexchanges.Other
mechanisms may account for FS-related respiratory adverse
effects.
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